**Table 2: Clinical presentation and presence of comorbidities of influenza-like illnesses in pregnant and postpartum women with SARS confirmed by COVID-19 and by Other confirmed agents**

| **Symptom, N (%)** | **COVID-19** | **Other confirmed agents** | **p** | **Effect size\*** |
| --- | --- | --- | --- | --- |
| Fever  Yes  No  Blank  Ignored | 10129 (52·9%) | 1803 (80·7%) | < 0·001 | 0·18 |
| 6318 (33·0%) | 378 (16·9%) |
| 2519 (13·2%) | 38 (1·7%) |
| 172 (0·9%) | 14 (0·6%) |
| Cough  Yes  No  Blank  Ignored | 12882 (67·3%) | 2022 (90·6%) | < 0·001 | 0·16 |
| 4273 (22·3%) | 173 (7·7%) |
| 1834 (9·6%) | 32 (1·4%) |
| 145 (0·8%) | 6 (0·3%) |
| Sore throat  Yes  No  Blank  Ignored | 3917 (20·5) | 913 (40·9%) | < 0·001 | 0·19 |
| 10683 (55·8%) | 1191 (53·3%) |
| 4251 (22·2%) | 77 (3·4%) |
| 287 (1·5%) | 52 (2·3%) |
| Dyspnea  Yes  No  Blank  Ignored | 10721 (56·0%) | 1438 (64·4%) | < 0·001 | 0·10 |
| 5884 (30·7%) | 729 (32·2%) |
| 2391 (12·5%) | 56 (2·5%) |
| 140 (0·7%) | 20 (0·9%) |
| Respiratory discomfort  Yes  No  Blank  Ignored | 8424 (44·0%) | 1495 (67·0%) | < 0·001 | 0·16 |
| 7267 (38·0%) | 643 (28·8%) |
| 3239 (16·9%) | 69 (3·1%) |
| 208 (1·1%) | 26 (1·2%) |
| O2 saturation < 95%  Yes  No  Blank  Ignored | 7187 (37·6%) | 675 (30·2%) | < 0·001 | 0·16 |
| 8315 (43·4%) | 1388 (62·2%) |
| 3391 (17·7%) | 93 (4·2%) |
| 245 (1·3%) | 77 (3·4%) |
| Diarrhea  Yes  No  Blank  Ignored | 1847 (9·7%) | 54 (2·4%) | <0·001 | 0·25 |
| 12270 (64·1%) | 784 (35·1%) |
| 4746 (24·8%) | 1369 (61·3%) |
| 275 (1·4%) | 26 (1·2%) |
| Heart disease  Yes  No  Blank  Ignored | 1157 (6·0%) | 54 (2·4%) | < 0·001 | 0·25 |
| 5945 (31·1%) | 1517 (68·4%) |
| 11899 (62·2%) | 617 (27·6%) |
| 137 (0·7%) | 45 (2·0%) |
| Chronic lung disease  Yes  No  Blank  Ignored | 117 (0·6%) | 115 (5·1%) | < 0·001 | 0·26 |
| 6660 (34·8%) | 1452 (65·0%) |
| 12212 (63·8%) | 620 (27·8%) |
| 149 (0·8%) | 46 (2·1%) |
| Chronic kidney disease  Yes  No  Blank  Ignored | 124 (0·6%) | 8 (0·4%) | < 0·001 | 0·23 |
| 6607 (34·5%) | 1553 (69·5%) |
| 12263 (64·1%) | 627 (28·1%) |
| 144 (0·8%) | 45 (2·0%) |
| Obesity  Yes  No  Blank  Ignored | 1183 (6·2%) | 61 (2·7%) | < 0·001 | 0·24 |
| 5868 (30·7%) | 1489 (66·7%) |
| 11922 (62·3%) | 639 (28·6%) |
| 165 (0·9%) | 44 (2·0%) |

COVID-19: Coronavirus Disease 2019; N: number; p: p-value; %: percentage·

\* Effect size given by Cramer’s V